ERBB2 and osteosarcoma: More recently, the anticancer efficacy of an attenuated therapeutic vaccine called ADXS31–164, consisting of recombinant Listeria monocytogenes expressing a human chimeric protein HER2/neu, has been evaluated in dogs with osteosarcoma, resulting in a longer disease-free interval and survival compared with standard of care (SOC) treatment [11].